Ipsen secures FDA approval for Sohonos to treat rare genetic disease FOP
French biopharmaceutical company Ipsen has received the US Food and Drug Administration (FDA) approval for Sohonos (palovarotene) capsules to treat fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder